Publicaciones en colaboración con investigadores/as de Assistance Publique -Hopitaux De Paris (13)

2024

  1. Considering nutritional status to improve outcomes of patients treated by atezolizumab–bevacizumab for advanced hepatocellular carcinoma

    Liver International

2023

  1. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

    The Lancet. Oncology, Vol. 24, Núm. 12, pp. 1411-1422

  2. Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY (Leukemia, (2023), 37, 2, (339-347), 10.1038/s41375-022-01802-y)

    Leukemia

  3. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY

    Leukemia, Vol. 37, Núm. 2, pp. 339-347

  4. Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes

    The Lancet. Oncology, Vol. 24, Núm. 1, pp. 91-106

2022

  1. Clinical, histological and molecular profiling of different stages of alcohol-related liver disease

    Gut, Vol. 71, Núm. 9, pp. 1856-1866

2021

  1. Endothelial dysfunction markers predict short-term mortality in patients with severe alcoholic hepatitis

    Hepatology International, Vol. 15, Núm. 4, pp. 1006-1017

2020

  1. Distinct mutational pattern of myelodysplastic syndromes with and without 5q– treated with lenalidomide

    British Journal of Haematology

2019

  1. Current and innovative emerging therapies for porphyrias with hepatic involvement

    Journal of Hepatology, Vol. 71, Núm. 2, pp. 422-433

2017

  1. A phosphokinome-based screen uncovers new drug synergies for cancer driven by liver-specific gain of nononcogenic receptor tyrosine kinases

    Hepatology, Vol. 66, Núm. 5, pp. 1644-1661

2015

  1. Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types

    Journal of the National Cancer Institute, Vol. 107, Núm. 12

2012

  1. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: Comparative analysis of the Macdonald, RECIST, RANO, and RECIST F criteria

    Neuro-Oncology, Vol. 14, Núm. 5, pp. 667-673

2006

  1. Can bone marrow-derived multipotent adult progenitor cells regenerate infarcted myocardium?

    Cardiovascular Research, Vol. 72, Núm. 1, pp. 175-183